MYCOBACTERIUM-VACCAE IN IMMUNOPROPHYLAXIS AND IMMUNOTHERAPY OF LEPROSY AND TUBERCULOSIS

被引:77
|
作者
STANFORD, JL
ROOK, GAW
BAHR, GM
DOWLATI, Y
GANAPATI, R
SAIDI, KG
LUCAS, S
RAMU, G
TORRES, P
LY, HM
ANSTEY, N
机构
[1] KUWAIT UNIV, FAC MED, DEPT MICROBIOL, KUWAIT, KUWAIT
[2] LEPROSY ORG IRAN, TEHRAN, IRAN
[3] BOMBAY LEPROSY PROJECT, BOMBAY, MAHARASHTRA, INDIA
[4] UNIV TEHRAN, SCH PUBL HLTH, TEHRAN, IRAN
[5] UNIV COLL & MIDDLESEX SCH MED, DEPT HISTOPATHOL, LONDON WC1E 6JJ, ENGLAND
[6] SACRED HEART LEPROSY CTR, KUMBAKONAM, TAMIL NADU, INDIA
[7] SANATORIO FONTILLES, ALICANTE, SPAIN
[8] NATL INST HYG & EPIDEMIOL, HANOI, VIETNAM
关键词
immunoprophylaxis; immunotherapy; leprosy; Mycobacterium vaccae; tuberculosis;
D O I
10.1016/0264-410X(90)90002-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Both leprosy and tuberculosis present continuing problems in their control, especially in the developing world, despite the availability of drugs effective in producing a bacteriological cure. Improved immunoprophylaxis, and an effective immunotherapy to be used with chemotherapy are urgently required. Intradermal injection of a suspension of killed Myobacterium vaccae promotes cell-mediated responses to antigens common to all mycobacteria, and switches off the tissue-necrotizing aspects of the Koch phenomenon. These properties led to the use of the suspensions as an improved vaccine, either alone or in combination with BCG. The same properties led to the employment of the suspension in immunotherapy as an adjunct to chemotherapy in the treatment of both leprosy and tuberculosis. The evidence leading to these conclusions is reviewed and discussed. © 1990.
引用
下载
收藏
页码:525 / 530
页数:6
相关论文
共 50 条
  • [1] MYCOBACTERIUM-VACCAE IMMUNOTHERAPY
    ONYEBUJOH, P
    ROOK, G
    LANCET, 1991, 338 (8781): : 1534 - 1534
  • [2] IMPROVED IMMUNOTHERAPY FOR PULMONARY TUBERCULOSIS WITH MYCOBACTERIUM-VACCAE
    BAHR, GM
    SHAABAN, MA
    GABRIEL, M
    ALSHIMALI, B
    SIDDIQUI, Z
    CHUGH, TD
    DENATH, FM
    SHAHIN, A
    BEHBEHANI, K
    CHEDID, L
    ROOK, GAW
    STANFORD, JL
    TUBERCLE, 1990, 71 (04): : 259 - 266
  • [3] IMMUNOTHERAPY OF TUBERCULOSIS WITH MYCOBACTERIUM-VACCAE NCTC-11659
    STANFORD, JL
    STANFORD, CA
    IMMUNOBIOLOGY, 1994, 191 (4-5) : 555 - 563
  • [4] IMMUNOTHERAPY WITH MYCOBACTERIUM-VACCAE AS AN ADJUNCT TO CHEMOTHERAPY IN THE TREATMENT OF PULMONARY TUBERCULOSIS
    STANFORD, JL
    BAHR, GM
    ROOK, GAW
    SHAABAN, MA
    CHUGH, TD
    GABRIEL, M
    ALSHIMALI, B
    SIDDIQUI, Z
    GHARDANI, F
    SHAHIN, A
    BEHBEHANI, K
    TUBERCLE, 1990, 71 (02): : 87 - 93
  • [5] AN INVESTIGATION OF PATIENTS WITH PULMONARY TUBERCULOSIS IN KUWAIT IN PREPARATION FOR STUDIES OF IMMUNOTHERAPY WITH MYCOBACTERIUM-VACCAE
    BAHR, GM
    STANFORD, JL
    CHUGH, TD
    SHAABAN, MA
    GABRIEL, M
    ALSHIMALI, B
    SIDDIQUI, Z
    GHARDANI, F
    ROOK, GAW
    SHAHIN, A
    BEHBEHANI, K
    TUBERCLE, 1990, 71 (02): : 77 - 86
  • [6] MYCOBACTERIUM-VACCAE AND IMMUNE-RESPONSES - IMPLICATIONS FOR LEPROSY CONTROL
    SWINBURNE, S
    BROWN, IN
    BROWN, CA
    LEPROSY REVIEW, 1985, 56 (03) : 209 - 220
  • [7] BIODEGRADATION OF TRICHLOROETHYLENE BY MYCOBACTERIUM-VACCAE
    VANDERBERG, LA
    BURBACK, BL
    PERRY, JJ
    CANADIAN JOURNAL OF MICROBIOLOGY, 1995, 41 (03) : 298 - 301
  • [8] IMMUNOTHERAPY WITH MYCOBACTERIUM-VACCAE AS AN ADDITION TO CHEMOTHERAPY FOR THE TREATMENT OF PULMONARY TUBERCULOSIS UNDER DIFFICULT CONDITIONS IN AFRICA
    ONYEBUJOH, PC
    ABDULMUMINI, T
    ROBINSON, S
    ROOK, GAW
    STANFORD, JL
    RESPIRATORY MEDICINE, 1995, 89 (03) : 199 - 207
  • [9] Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis
    Stanford, J
    Stanford, C
    Grange, J
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 1701 - 1719
  • [10] Immunotherapy with Mycobacterium vaccae and the treatment of tuberculosis
    Stanford, JL
    Stanford, CA
    JOURNAL OF APPLIED BACTERIOLOGY, 1996, 81 : S81 - S86